Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Companies Dig Into Sunshine Rule Details In Preparation For Aug. 1 Go-Live Date

This article was originally published in The Gray Sheet

Executive Summary

CMS has finalized several sunshine rule provisions: the definition of “applicable manufacturer” has been narrowed; many payments to speakers at continuing medical education programs and events need not be reported; and the agency will allow manufacturers to supply contextual information on the public database.

You may also be interested in...

Device Firms Would Have To Report Value Of Device Samples For Patient Use Under STAR Act

An amendment to the Physician Payment Sunshine Act approved by a House Committee on April 9 would require device manufacturers to report the value of any samples given to physicians, a requirement that could include some free samples a doctor uses when educating his patients on device use.

Company Payments To Teaching Hospitals Hard To Distinguish In Open Payments

Both manufacturers and hospital-system personnel are complaining to CMS that payments by firms to non-teaching hospitals are becoming confused with payments to teaching hospitals in the public Open Payments database.

CMS Lets Context Stand In Open Payments Database

Device firm representatives were pleased, at least on first review, with CMS’ presentation of the industry-submitted physician payment data posted online for the first time Sept. 30, including the public context provided for the database.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts